The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     



Published Online, 15 April 2008, www.theannals.com, DOI 10.1345/aph.1K605.
The Annals of Pharmacotherapy: Vol. 42, No. 5, pp. 680-685. DOI 10.1345/aph.1K605
© 2008 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Google Scholar
Right arrow Articles by Carroll, D. N
Right arrow Articles by Carroll, D. G
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carroll, D. N
Right arrow Articles by Carroll, D. G

DRUG INTERACTIONS

Interactions Between Warfarin and Three Commonly Prescribed Fluoroquinolones

Douglas N Carroll, PharmD BCPS

Clinical Associate Professor, Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Tuscaloosa, AL

Dana G Carroll, PharmD BCPS

Clinical Associate Professor, Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University

Reprints: Dr. Douglas Carroll, Box 870374, Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Tuscaloosa, AL 35487, fax 205/348-2889, carrodn{at}auburn.edu

OBJECTIVE: To critically evaluate a possible increased anticoagulant response during concomitant warfarin and fluoroquinolone therapy.

DATA SOURCES: A literature search was conducted using PubMed, International Pharmaceutical Abstracts, and MEDLINE, from inception to January 2008, combining the term warfarin individually with ciprofloxacin, levofloxacin, and moxifloxacin. These 3 quinolones were selected based on their commercial availability and use in the US.

STUDY SELECTION AND DATA EXTRACTION: All publication types including human participants and published in English were eligible for review. Reports were selected based on the use of typical treatment courses of fluoroquinolones during concomitant warfarin therapy and the reporting of prothrombin time (PT) or international normalized ratio (INR).

DATA SYNTHESIS: Twenty-two publications were evaluated including 16 case reports or case series, 2 retrospective cohort studies, and 4 prospective studies, which included 2 placebo-controlled investigations. Identified reports covered a wide range of patient ages with multiple comorbidities. Changes in PT and INR values were considerably variable and inconsistent during concomitant warfarin and fluoroquinolone therapy. Results from the 6 structured reports demonstrated mean increases in PT and INR values that were clinically insignificant. However, some patients experienced significant increases above the desired therapeutic range. Increased anticoagulation was typically observed within the first week of concomitant fluoroquinolone therapy. Bleeding complications during times of increased anticoagulation were not always observed, but did result in death for 2 patients.

CONCLUSIONS: Published data show no consistent increase in anticoagulant effects during concomitant warfarin and 3 commonly prescribed fluoroquinolones. Therefore, more frequent monitoring during concomitant therapy would be prudent.

Key Words: ciprofloxacin, levofloxacin, moxifloxacin, warfarin

Published Online, April 15, 2008. www.theannals.com, DOI 10.1345/aph.1K605

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER:
407-000-08-009-H01





homecopy help contact us subscription past issues search current issue
Copyright © 2008 by Harvey Whitney Books Company.